Modality
Gene Editing
MOA
FXIai
Target
ALK
Pathway
Fibrosis
DLBCLTTR AmyloidosisMelanoma
Development Pipeline
Preclinical
~Apr 2020
→ ~Jul 2021
Phase 1
Oct 2021
→ Nov 2028
Phase 1Current
NCT06829096
2,023 pts·Melanoma
2024-06→TBD·Terminated
NCT06260322
1,214 pts·Melanoma
2021-10→2028-11·Not yet recruiting
3,237 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-11-072.6y awayPh2 Data· Melanoma
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
P1/2
Termina…
Catalysts
Ph2 Data
2028-11-07 · 2.6y away
Melanoma
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06829096 | Phase 1/2 | Melanoma | Terminated | 2023 | VA |
| NCT06260322 | Phase 1/2 | Melanoma | Not yet recr... | 1214 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| GSK-6983 | GSK | Phase 2 | ALK | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK |